Sees FY26 revenue flat to up 1.5%.”As we look ahead, we are cautiously optimistic that positive demand trends will continue in 2026. We remain committed to driving our strategy forward, including through selective and strategic acquisitions that align with our core competencies; taking decisive actions to drive efficiency and process improvements that will deliver continued benefits; and by strengthening and refining our organization to enhance our speed and responsiveness. This approach ensures Charles River (CRL) remains the partner of choice for our clients as the biopharmaceutical demand environment continues to improve,” Foster concluded.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRL:
- Charles River reports Q4 EPS $2.39, consensus $2.35
- CRL Upcoming Earnings Report: What to Expect?
- CRO peers lower after Medpace earnings, comments on cancellations
- Charles River price target raised to $251 from $197 at TD Cowen
- Charles River, Gazi University Faculty of Medicine enter manufacturing pact